Asia FX weakens slightly, rupee recovers from record low as RBI holds rates
Investing.com - Cantor Fitzgerald has maintained its Overweight rating and $200.00 price target on Ascendis Pharma (NASDAQ:ASND) ahead of the company’s second-quarter earnings report scheduled for Thursday. The stock, currently trading near its 52-week high of $183, has surged over 42% in the past six months. According to InvestingPro data, analyst targets range from $195 to $302, reflecting strong bullish sentiment with a consensus rating of 1.19.
The research firm expects Yorvipath U.S. sales to exceed $93 million in the second quarter, a threshold that could potentially drive the stock higher according to Cantor’s buyside survey.
Cantor Fitzgerald noted that even in its worst-case scenario analysis, Yorvipath sales should surpass this key performance benchmark.
The Wall Street consensus estimate for Yorvipath sales currently stands at $83 million, which the research firm characterized as "very conservative."
Ascendis Pharma is set to release its complete second-quarter financial results on August 7, 2025.
In other recent news, Ascendis Pharma has reported several notable developments. The company is set to release its second-quarter earnings, with Cantor Fitzgerald maintaining an Overweight rating and a $200 price target. The firm anticipates Yorvipath U.S. sales to potentially exceed $93 million for the quarter. Additionally, the U.S. Food and Drug Administration (FDA) has approved Ascendis Pharma’s SKYTROFA for treating growth hormone deficiency in adults, expanding its previous approval for pediatric use. This marks a significant milestone for the company in broadening its treatment offerings.
Moreover, Ascendis Pharma has announced positive three-year data from its Phase 3 PaTHway Trial for TransCon PTH, indicating sustained benefits for adults with hypoparathyroidism. These findings were presented at the ENDO 2025 conference, highlighting improvements in biochemical markers and quality of life measures. In another analyst update, Morgan Stanley (NYSE:MS) has assumed coverage of Ascendis Pharma with an Overweight rating and a $250 price target, citing the promising commercial trajectory of Yorvipath. These developments reflect a period of significant activity and potential growth for Ascendis Pharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.